OP White Papers - random

1. Modern Modeling Tools For Small Molecule Solid Dose Manufacturing 3/10/2025

   Data-driven modeling techniques can enhance scale-up processes, streamline production, and help companies navigate the complexities of modern drug development with greater precision and reliability.

2. Ready To Demystify Organoids? 7/1/2025

   Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.

3. Optimizing DSP Development: Faster Timelines, Lower Costs, And High-Quality Processes 4/8/2025

   The biopharmaceutical industry faces growing downstream processing challenges in purifying complex biologics efficiently and at scale.

4. If You Can't Win The Game, Change It 12/11/2024

   Explore how eData sharing is used in the biopharma market, enabling standardized, collaborative supply chains that reduce risks and enhance visibility while improving capacity planning.

5. Nitrosamine Analysis: Solutions For Risk Management And Analytical Testing 8/22/2024

   Testing for nitrosamines is essential in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and drug products to ensure safety and compliance.

6. Bispecific Antibodies Unleashed 5/16/2024

   Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

7. Aggregation In Antibody-Drug Conjugates: Causes And Mitigation 9/1/2025

   Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.

8. Analytical Approach For Bispecific Antibody Quality Study 11/25/2025

   Bispecific antibody quality control demands advanced analytics to detect mispaired species, assess structural integrity, and confirm potency, ensuring safety and efficacy across diverse therapeutic applications.

9. Transitioning Your Product From Phase 1 To Phase 2 Clinical Studies 12/13/2024

   Strategic partnerships can streamline your transition from Phase 1 to Phase 2 clinical studies, ensuring optimized dosage forms, seamless scale-up, and alignment with patient and study requirements.

10. AAV-Based Gene Editing For Huntington's Disease 10/28/2025

    LETI-101 uses AAV5 to deliver a compact CRISPR system for allele-selective editing of mutant HTT, showing promise as a one-time treatment for Huntington’s disease with strong preclinical safety and efficacy.